Multi-ancestry study of the genetics of problematic alcohol use in >1 million individuals

Hang Zhou[1,2,46], Rachel L. Kember[3,4,46], Joseph D. Deak[1,2], Heng Xu[4], Sylvanus Toikumo[3,4], Kai Yuan[5,6], Penelope A. Lind[7,8,9], Leila Farajzadeh[10,11,12], Lu Wang[1,2], Alexander S. Hatoum[13], Jessica Johnson[14,15], Hyunjoon Lee[16], Travis T. Mallard[5,16,17], Jiayi Xu[1], Keira J.A. Johnston[1], Emma C. Johnson[18], Marco Galimberti[1,2], Cecilia Dao[2,19], Daniel F. Levey[1,2], Cassie Overstreet[1,2], Enda M. Byrne[20], Nathan A. Gillespie[21], Scott Gordon[22], Ian B. Hickie[23], John B. Whitfield[22], Ke Xu[1,2], Hongyu Zhao[24,25], Laura M. Huckins[1], Lea K. Davis[26,27,28], Sandra Sanchez-Roige[27,29], Pamela A. F. Madden[18], Andrew C. Heath[18], Sarah E. Medland[7,9,30], Nicholas G. Martin[22], Tian Ge[5,31,32], Jordan W. Smoller[5,31,33], David M. Hougaard[11,34,], Anders D. Børglum[10,11,12], Ditte Demontis[10,11,12], John H. Krystal[1,2,35,36], J. Michael Gaziano[37,38,39], Howard J. Edenberg[40,41,] Arpana Agrawal[18], Million Veteran Program[*], Amy C. Justice[2,42,43], Murray B. Stein[29,44,45,] Henry R. Kranzler[3,4,47], and Joel Gelernter[1,2,24,35,47]

[1]Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA
[2]Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
[3]Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA
[4]Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
[5]Stanley Center for Psychiatric Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
[6]Analytic and Translational Genetics Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
[7]Psychiatric Genetics, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[8]School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia
[9]Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia
[10]Department of Biomedicine - Human Genetics, Aarhus University, Aarhus, Denmark
[11]The Lundbeck Foundation Initiative for Integrative Psychiatric Research, iPSYCH, Denmark
[12]Center for Genomics and Personalized Medicine, Aarhus, Denmark
[13]Department of Psychological and Brain Sciences, Washington University in St. Louis, Saint Louis, MO, USA
[14]Pamela Sklar Division of Psychiatric Genomics, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[15]Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA
[16]Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
[17]Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[18]Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, USA
[19]Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA
[20]Child Health Research Centre, The University of Queensland, Brisbane, QLD, Australia
[21]Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
[22]Genetic Epidemiology, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia
[23]Brain and Mind Centre, University of Sydney, Camperdown, NSW, Australia
[24]Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA

[25]Department of Genetics, Yale School of Medicine, New Haven, CT, USA
[26]Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA
[27]Department of Medicine, Division of Medical Genetics, Vanderbilt University Medical Center, Nashville, TN, USA
[28]Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
[29]Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
[30]School of Psychology, University of Queensland, Brisbane, QLD, Australia
[31]Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
[32]Center for Precision Psychiatry, Massachusetts General Hospital, Boston, MA, USA
[33]Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
[34]Center for Neonatal Screening, Department for Congenital Disorders, Statens Serum Institut, Copenhagen, Denmark
[35]Department of Neuroscience, Yale University School of Medicine, New Haven, CT, USA
[36]National Center for PTSD, US Department of Veterans Affairs, West Haven, CT, USA
[37]Massachusetts Veterans Epidemiology and Research Information Center (MAVERIC), Boston Veterans Affairs Healthcare System, Boston, MA, USA
[38]Department of Medicine, Divisions of Aging and Preventative Medicine, Brigham and Women's Hospital, Boston, MA, USA
[39]Department of Medicine, Harvard Medical School, Boston, MA, USA
[40]Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA
[41]Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
[42]Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
[43]Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, CT, USA
[44]VA San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA
[45]Herbert Wertheim School of Public Health and Human Longevity Science, University of California San Diego, La Jolla, CA, USA
[46]These authors contributed equally
[47]These authors jointly supervised this work
[*]A list of members and their affiliations appears in the Supplementary Information

Corresponding Authors:

Joel Gelernter, Department of Psychiatry, Yale School of Medicine, Veterans Affairs Connecticut Healthcare System, 116A2, 950 Campbell Ave, West Haven, CT 06516, USA. Email: joel.gelernter@yale.edu.

Hang Zhou, Department of Psychiatry, Yale School of Medicine; Veterans Affairs Connecticut Healthcare System, 43A35, 950 Campbell Ave, West Haven, CT 06516, USA. Email: hang.zhou@yale.edu

Abstract

Problematic alcohol use (PAU) is a leading cause of death and disability worldwide. To improve our understanding of the genetics of PAU, we conducted a large cross-ancestry meta-analysis of PAU in 1,079,947 individuals. We observed a high degree of cross-ancestral similarity in the genetic architecture of PAU and identified 110 independent risk variants in within- and cross-ancestry analyses. Cross-ancestry fine-mapping improved the identification of likely causal variants. Prioritizing genes through gene expression and/or chromatin interaction in brain tissues identified multiple genes associated with PAU. We identified existing medications for potential pharmacological studies by drug repurposing analysis. Cross-ancestry polygenic risk scores (PRS) showed better performance in independent sample than single-ancestry PRS. Genetic correlations between PAU and other traits were observed in multiple ancestries, with other substance use traits having the highest correlations. The analysis of diverse ancestries contributed significantly to the findings, and fills an important gap in the literature.

107 **Introduction**

108 Alcohol use disorder (AUD) is a chronic relapsing disease associated with a host of
109 adverse medical, psychiatric, and social consequences[1]. Given observed heritability (h^2~50%[2]),
110 there has been substantial progress made in genome-wide association studies (GWAS) of AUD
111 and problematic drinking[3-9], and also for measures of alcohol consumption[10,11]. A prior GWAS of
112 problematic alcohol use (PAU, a phenotype based on a meta-analysis of highly genetically
113 correlated (genetic correlations >0.7) AUD[7], alcohol dependence [AD][5], and AUDIT-P [Alcohol
114 Use Disorders Identification Test-Problem score, a measure of problematic drinking][4,12],
115 N=435,563) identified 29 independent risk variants, predominantly in European (EUR) ancestry
116 subjects[6]. Consistent with genetic studies of other complex traits, and the high polygenicity of
117 PAU, larger and more ancestrally-representative samples need to be examined to outline the
118 genetic architecture of these alcohol use traits.

119

120 A key finding from recent studies is that both AUD and AUDIT-P differ phenotypically
121 and genetically from typical alcohol consumption[4,7]. AUD and AUDIT-P index aspects of
122 disordered alcohol intake and correlate with genetic liability to negative psychiatric and
123 psychosocial factors (e.g., higher major depressive disorder [MDD], lower educational
124 attainment). An item-level study of the AUDIT questionnaire confirmed a two-factor structure at
125 the genetic level, underscoring unique genetic influences on alcohol consumption and alcohol-
126 related problems[13] and noted that the genetics of drinking frequency were confounded by socio-
127 economic status. A similar pattern – genetic distinctions between substance use disorder (SUD)
128 vs. non-dependent use – has also been observed for cannabis use disorder and cannabis use[14].
129 Furthermore, aggregating across multiple substance use disorders suggests that problematic
130 and disordered substance use has a unique genetic architecture that, while shared across
131 SUDs, does not overlap fully with non-dependent substance use *per se*[15].

132 Notwithstanding prior discovery of multiple genome-wide significant (GWS) loci for PAU,
133 there are major gaps in our understanding of its genetic underpinnings. First, the estimated
134 single-nucleotide polymorphism (SNP)-based heritability (h^2) of AUD and PAU ranges from 5.6%
135 to 10.0%[4-7], reflecting substantial "missing heritability" compared to estimates based on genetic
136 epidemiology, which show ~50% heritability[2]. Second, most of the available samples used in
137 human genetic studies – including for AUD – are of EUR ancestry; lack of ancestral diversity is
138 a major problem both for understanding the genetics of these traits, and for potential
139 applications of these genetic discoveries to global populations[16]. Our previous study in the
140 Million Veteran Program (MVP) analyzed AUD in multiple ancestral groups[7]. However, non-EUR
141 samples (N=72,387) were far smaller than EUR samples (N=202,004), resulting in inadequate
142 statistical power and unbalanced gene discovery across ancestral backgrounds, which limits our
143 understanding of the genetic architecture underlying the trait across populations.

144

145 To improve our understanding of the biology of PAU in multiple populations, we
146 conducted substantially larger ancestry-specific GWAS of PAU followed by a cross-ancestry
147 meta-analysis in 1,079,947 individuals from multiple cohorts. We identified 85 independent risk
148 variants in EUR participants (almost tripling the number identified in previous studies) and 110
149 in the within-ancestry and cross-ancestry meta-analyses. We investigated the shared genetic
150 architectures of PAU across different ancestries, performed fine-mapping for causal variants by
151 combining information from multiple ancestries, and tested cross-ancestry polygenic risk score
152 (PRS) associations with AUDIT-P in the UK Biobank (UKB) samples[17]. We combined genes
153 identified by gene-based association analysis, transcriptome-wide association analysis (TWAS)
154 and brain-chromatin interaction analysis, found dozens of genes linking to brain with convergent
155 evidence. Drug repurposing analysis identified potential medications for further pharmacological
156 studies, bringing forward the hope of novel biologically-directed medications strategies with the

157 further potential of personalization. We conducted phenome-wide PRS analyses in biobanks
158 from the PsycheMERGE Network[18] in AFR and EUR-ancestry samples. We tested the genetic
159 correlation between PAU and other traits, especially novel with respect to AFR samples where
160 such analyses could not be conducted previously. These findings substantially augment the
161 number of loci that contribute to risk of PAU, increasing power to investigate the causal
162 relationships of PAU with other diseases, and identify novel druggable targets whose
163 therapeutic potential requires empirical evaluation.

164

165 **Results**

166 **Ancestrally diverse data collection.** We collected newly genotyped subjects (most from MVP)
167 and previously published data from multiple cohorts (MVP[19], FinnGen[20], UKB[17], Psychiatric
168 Genomics Consortium (PGC)[5], iPSYCH[21,22], Queensland Berghofer Medical Research Institute
169 (QIMR) cohorts[23-25], Yale-Penn 3[26], and East Asian cohorts[27]) resulting in a total of 1,079,947
170 subjects (Table 1). Five ancestral groups were analyzed (Figure 1a): EUR (N=903,147), AFR
171 (N=122,571), Latin American (LA, N=38,962), East Asian (EAS, N=13,551, all published in ref.
172 27), and South Asian (SAS, N=1,716). As in our previous study[6], we utilized data on
173 International Classification of Diseases (ICD)-diagnosed AUD (N_{case}=136,182; $N_{control}$=692,594),
174 DSM-IV AD (N_{case}=29,770; $N_{control}$=70,282) and AUDIT-P (N=151,119), together defined as
175 problematic alcohol use (PAU; based on high genetic correlations across these measures). The
176 total number of AUD and AD cases was 165,952, almost double the 85,391 cases in the
177 previously largest study[28].

178

179 **Figure 1. Genetic architecture of problematic alcohol use (PAU). a**, Sample sizes in
180 different ancestral groups. **b**, Relationship between sample size and number of independent

181 variants identified. Kranzler et al., 2019: cross-ancestry meta-analysis for AUD; Zhou et al.,
182 2020: PAU in EUR. **c**, Lookup for cross-ancestry replication in AFR for the 85 independent
183 variants in EUR meta-analysis. Of the 85 variants, 76 could be analyzed in AFR (see Methods).
184 Sign test was performed for the number of variants with same direction of effect (64/76,
185 p=1.0×10^{-9}). 23 variants were nominally significant in AFR and 6 were significant after multiple
186 correction (p<0.05/76). **d**, Observed-scale and liability-scale SNP-based heritability (h^2) in
187 multiple ancestries. **e**, Cross-ancestry genetic-effect correlation (ρ_{ge}) and genetic-impact
188 correlation (ρ_{gi}) between EUR, AFR and LA ancestries. Error bar is the 95% confidence interval.
189 **f**, Genome-wide association results for PAU in the cross-ancestry meta-analysis. Red line is
190 significance threshold of 5×10^{-8}. EUR, European; AFR, African; LA, Latin American; EAS, East
191 Asian; SAS, South Asian; GWS, genome-wide significant.



192

193

194 **Table 1. Demographics for cohorts in the meta-analysis of PAU.** Cohorts are described in

195 the Methods. UKB-EUR1: genetically defined White-British by UK Biobank; UKB-EUR2:
196 genetically defined European non-White-British participants (see Methods); AGDS, the
197 Australian Genetics of Depression Study; TWINS, the Australian twin-family study of alcohol use
198 disorder; GBP, the Australian Genetics of Bipolar Disorder Study; iPSYCH1, phase 1 of iPSYCH;
199 iPSYCH2, phase 2 of iPSYCH; YP3, Yale-Penn 3; $N_{effective}$, effective sample size; Thai, study of
200 the genetics of methamphetamine dependence in Thailand; GSA, Illumina Global Screening
201 Array; MEGA, Illumina Multi-Ethnic Global Array; Cyto, Illumina Cyto12 array.

Cohorts	**Traits**	**N_{case}**	**$N_{control}$**	**N_{total}**	**N_{female} (%)**	**$N_{effective}$**	**Ref[a]**
European ancestry (EUR)							
MVP	AUD	80,028	368,113	448,141	33,345 (7.4)	262,947	[6] and new
FinnGen	AUD	8,866	209,926	218,792	123,579 (56.5)	34,027	New[b]
UKB-EUR1	AUDIT-P	-	-	132,001	74,113 (56.1)	132,001	[6] and new
UKB-EUR2	AUDIT-P	-	-	17,898	10,529 (58.5)	17,898	New
PGC	AD	9,938	30,992	40,930	20,933 (51.1)	23,075	[5][d]
QIMR_AGDS	AD	6,726	4,467	11,193	8,605 (76.9)	10,737	New
QIMR_TWINS	AD	2,772	5,630	8,402	4,922 (58.6)	7,430	[5] and new
QIMR_GBP	AD	1,287	751	2,038	1,435 (70.4)	1,897	New
iPSYCH1	AD	2,117	13,238	15,355	8,077 (52.6)	7,301	New
iPSYCH2	AD	1,024	5,732	6,756	3,607 (53.4)	3,475	New
YP3	AD	567	1,074	1,641	854 (52.0)	1,484	New
Sub_total	**PAU**	**113,325**	**639,923**	**903,147**	**289,999 (32.1)**	**502,272**	
African ancestry (AFR)							
MVP	AUD	36,330	79,100	115,430	16,084 (13.9)	99,583	[7] and new
PGC	AD	3,335	2,945	6,280	3,124 (49.7)	4,991	[5]
YP3	AD	451	410	861	430 (50.0)	959	New
Sub_total	**AUD**	**40,116**	**82,455**	**122,571**	**19,638 (16.0)**	**105,433**	
Latin American ancestry (LA)							
MVP	**AUD**	**10,150**	**28,812**	**38,962**	**3,731 (9.6)**	**30,023**	[7] and new
East Asian[a] ancestry (EAS)							
MVP	AUD	701	6,254	6,955	747 (10.7)	2,521	[27]
Han Chinese–GSA	AD	533	2,848	3,381	1,012 (29.9)	1,796	
Thai METH–MEGA	AD	794	1,576	2,370	1,008 (42.5)	2,112	
Thai METH–GSA	AD	127	405	532	263 (49.4)	387	
Han Chinese–Cyto	AD	99	214	313	0 (0)	271	
Sub_total	**AUD**	**2,254**	**11,297**	**13,551**	**3,030 (22.4)**	**7,087**	
South Asian ancestry (SAS)							
MVP	AUD	107	389	496	67 (13.5)	336	[7] and new
UKB-SAS	AUDIT-P	-	-	1,220	535 (43.9)	1,220	New
Sub_total	**PAU**	**107**	**389**	**1,716**	**602 (35.1)**	**1,556**	
Total	**PAU**	**165,952**	**762,876**	**1,079,947**	**317,000 (29.4)**	**646,371**	

202 Note: [a]data either published in previous alcohol GWAS or newly included for this project.
203 [b]FinnGen summary statistics were downloaded from FinnGen data freeze v5
204 (https://r5.finngen.fi/). [c]Included related subjects from UKB. [d]Reran the PGC AD GWAS in EUR
205 excluding two Australian cohorts.

206

207 **Genome-wide association results for PAU.** We performed GWAS and within-ancestry meta-
208 analyses for PAU in five ancestral groups and then completed a cross-ancestry meta-analysis.
209 In the EUR meta-analysis, 113,325 cases of AUD/AD, 639,923 controls and 149,899
210 participants with AUDIT-P scores were analyzed (Supplementary Figure 1a). After conditional
211 analysis, 85 independent variants at 75 loci reached GWS (Methods, Supplementary Table 1)
212 (see also Figure 1b). Of these variants, 41 are in protein-coding genes; of these, 5 are missense
213 variants (*GCKR**rs1260326; *ADH1B**rs75967634; *ADH1B**rs1229984; *SCL39A8**rs13107325;
214 *BDNF**rs6265).

215

216 Due to the smaller sample numbers, the non-EUR GWAS yielded fewer variants
217 associated with PAU than did the EUR GWAS (Supplementary Table 1). The AFR meta-
218 analysis found two independent *ADH1B* missense variants (rs1229984 and rs2066702)
219 associated with AUD (Figure 1b, Supplementary Figure 1b); these were reported previously[7,26].
220 In the LA samples from MVP, only *ADH1B**rs1229984 (lead SNP) was identified
221 (Supplementary Figure 1c). Two independent risk variants, *ADH1B**rs1229984 and
222 *BRAP**rs3782886, were reported in EAS previously[27,29]. In the small SAS meta-analysis, one
223 intergenic variant (rs12677811) was associated with AUD; however, this SNP was present only
224 in the UKB (Supplementary Figure 1d).

225

226 Of the 85 lead variants identified in the EUR GWAS, 76 were either directly analyzed or
227 had proxy variants in AFR (Methods, Supplementary Table 2, Figure 1c), 64 of which had the

228 same direction of effect (sign test p=1.00×10^{-9}). Of these, 23 were nominally associated (p<0.05)
229 and 6 were significantly associated with AUD after multiple-testing correction (p<6.58×10^{-4}). In
230 LA, 15 of the EUR GWS variants were nominally significant (p<0.05) and 2 were significantly
231 associated with AUD (rs12048727 and rs1229984). In EAS, 5 variants were nominally
232 significant and two were significantly associated with AUD (rs1229984 and rs10032906). Only
233 two variants were nominally associated with PAU in SAS (rs1229984 was not present in SAS).

234

235 We estimated the SNP-based heritability (h^2) for PAU and AUD (excluding AUDIT-P
236 from UKB) in EUR, AFR and LA; significant h^2 estimates (range from 0.066 to 0.127) were
237 observed (Figure 1d, Supplementary Table 3).

238

239 High genetic correlations were observed across the EUR, AFR, and LA ancestries
240 (Figure 1e, Supplementary Table 4). The genetic-effect correlation (ρ_{ge}) is 0.71 (SE=0.09,
241 p=6.16×10^{-17}) between EUR and AFR, 0.85 (SE=0.09, p=3.14×10^{-22}) between EUR and LA, and
242 0.88 (SE=0.18, p=1.58×10^{-6}) between AFR and LA. The genetic-impact correlation (ρ_{gi}) is 0.67
243 (SE=0.07, p=2.78×10^{-21}) between EUR and AFR, 0.86 (SE=0.09, p=3.52×10^{-20}) between EUR
244 and LA, and 0.72 (SE=0.16, p=9.63×10^{-6}) between AFR and LA. The estimates involving
245 smaller study populations were not robust (Bonferroni p>0.05).

246

247 In the cross-ancestry meta-analysis of all available datasets, we identified 100
248 independent variants at 90 loci (Figure 1f, Supplementary Table 1); 80 are novel findings for
249 PAU. Of these, 53 variants were located in protein-coding genes, of which 9 are missense
250 variants: *GCKR**rs1260326; *ADH1B**rs75967634, rs1229984, and rs2066702;
251 *SCL39A8**rs13107325; *OPRM1**rs1799971; *SLC25A37**rs2942194; *BDNF**rs6265; and

252 *BRAP**rs3782886. The cross-ancestry meta-analysis identified 24 more risk variants than the
253 EUR meta-analysis, but 9 EUR variants fell below GWS (p-values ranging from 5.26×10^{-6} to
254 9.84×10^{-8}). In total, 110 unique variants were associated with PAU in either the within-ancestry
255 or cross-ancestry analyses (Figure 1b, Supplementary Table 1).

256

257 **Within- and cross-ancestry causal variant fine-mapping.** We performed within-ancestry fine-
258 mapping for the 85 clumped regions with independent lead variants in EUR (Supplementary
259 Tables 5 and 6). A median number of 115 SNPs were included in each region to estimate the
260 credible sets with 99% posterior inclusion probability (PIP) of causal variants. After fine-mapping,
261 the median number of SNPs constituting the credible sets was reduced to 20. Among the 85
262 regions, there were 5 credible sets that include only a single variant with PIP ≥99% (presumably
263 indicating successful identification of specific causal variants): rs1260326 in *GCKR*, rs472140
264 and rs1229984 in *ADH1B*, rs2699453 (intergenic), and rs2098112 (intergenic). Another 19
265 credible sets contained ≤5 variants (Figure 2a).

266

267 **Figure 2. Fine-mapping for PAU. a**, Fine-mapping of causal variants in 85 regions in EUR. **b**,
268 92 regions in cross-ancestry analysis were fine-mapped and a direct comparison was done for
269 these regions in EUR. **c**, Comparison for the highest PIPs from cross-ancestry and EUR-only
270 fine-mapping in the 92 regions. Red dots are the regions fine-mapped across EUR, AFR, and
271 LA; blue dots are the regions fine-mapped across EUR and AFR; green dots are the regions
272 fine-mapped across EUR and LA; black dots are the regions only fine-mapped in EUR. FM, fine-
273 mapping.



We performed cross-ancestry fine-mapping to identify credible sets with 99% PIP for causal variants proximate to 92 independent lead variants in the cross-ancestry meta-analysis (Supplementary Tables 7 and 8). The median number of SNPs in the credible sets was 9. 13 credible sets contain only a single variant with PIP ≥99%; 47 credible sets contain ≤5 variants (Figure 2b). For example, fine-mapping the region proximate to lead SNP rs12354219 (which maps to *DYPD* on chromosome 1) identified rs7531138 as the most likely potential causal variant (PIP=48%), although this variant and rs12354219 (PIP=11%) are in high linkage disequilibrium (LD) in different populations (r^2 ranges from 0.76 to 0.99). In a cross-ancestry meta-analysis rs7531138 showed significant association with schizophrenia (p=1.04×10^{-8}), but rs12354219 (p=6.18×10^{-8}) did not[30] (although the two p-values were very similar). rs7531138 is also a lead SNP associated with educational attainment (p=1.74×10^{-11}), unlike rs12354219 (p>5×10^{-8})[31].

288

289 To compare within- and cross-ancestry fine-mapping, we performed fine-mapping for the
290 above 92 regions using the same SNP sets and EUR-only LD information (Figure 2b & 2c). The
291 median number of SNPs in the credible sets is 13, with 7 credible sets containing a single
292 variant and 26 containing ≤5 variants, indicating that cross-ancestry fine-mapping improved
293 causal variant identification, consistent with other studies reporting improved fine-mapping by
294 including other ancestries[11].

295

296 **Gene-based association analysis.** We used MAGMA[32,33] to perform gene-based association
297 analyses. 130 genes in EUR, 9 in AFR and 6 in LA (for AFR and LA populations, all mapped to
298 the ADH gene cluster), and 7 in EAS (mapped to either the ADH gene cluster or the *ALDH2*
299 region[27]) were associated with PAU or AUD (Supplementary Table 9). There were no significant
300 findings in SAS.

301

302 **Transcriptome-wide association analyses (TWAS).** We used S-PrediXcan[34] to identify
303 predicted gene expression associations with PAU in 13 brain tissues[35]. 426 significant gene-
304 tissue associations were identified, representing 89 unique genes (Supplementary Table 10).
305 Five genes showed associations with PAU in all available brain tissues, including *AMT*
306 (Aminomethyltransferase), *YPEL3* (Yippee Like 3), *EVI2A* (Ecotropic Viral Integration Site 2A),
307 *EVI2B* (Ecotropic Viral Integration Site 2B), and *CTA-223H9.9* (lncRNA). We also observed
308 associations between PAU and the expression of alcohol dehydrogenase genes (*ADH1B* in the
309 putamen (basal ganglia), *ADH1C* in 10 brain tissues, and *ADH5* in cerebellar hemisphere and
310 cerebellum). Among the brain tissues, caudate (basal ganglia) had the most genes whose
311 expression was associated with PAU (42 genes), followed by the putamen (basal ganglia) (39

genes). TWAS that integrated evidence across 13 brain tissues using S-MultiXcan[36] to test joint effects of gene expression variation identified 121 genes (81 shared with S-PrediXcan) whose expression was associated with PAU (Supplementary Table 11).

Linking risk genes to brain chromatin interaction. We used H-MAGMA[37] to implicate risk genes associated with PAU by incorporating brain chromatin interaction profiles. 1,030 gene-chromatin associations were identified in 6 brain Hi-C annotations, representing 401 unique genes (Supplementary Table 12). 58 genes showed association with chromatin interaction in all 6 annotations, including *ADH1B*, *ADH1C*, *DRD2*, *EVI2A* and others that also showed evidence by TWAS in brain tissues.

Convergent evidence linking association to brain. We examined overlapped genes by both gene-based association analysis and TWAS in brain tissues and/or H-MAGMA analysis using Hi-C brain annotations. Among the 130 genes associated with PAU in EUR, 60 were also implicated by TWAS findings either by single brain tissue (S-PrediXcan) or across brain tissues (S-MultiXcan), 82 have evidence of brain chromatin interaction, and 38 have evidence from both TWAS and Hi-C annotations including *ADH1B*, *DRD2*, *KLB* and others (Supplementary Table 9).

Probabilistic fine-mapping of TWAS. We performed fine-mapping for TWAS using FOCUS[38], a method that estimates credible gene sets predicted to include the causal gene that can be prioritized for functional assays. We detected 53 credible sets at a nominal confidence level (set at 90% PIP). These contained 145 gene-tissue associations with an average PIP of 32% (Supplementary Table 13). For the 19 gene-tissue associations having PIP >90%, 9 are from brain tissues (e.g., *ZNF184* expression in hypothalamus (PIP=0.94%), *MTCH2* expression in

336 nucleus accumbens (basal ganglia) (PIP=99%), *SLC4A8* expression in dorsolateral prefrontal
337 cortex (PIP=98%), *YPEL3* expression in cerebellum (PIP=100%), and *CHD9* expression in
338 dorsolateral prefrontal cortex (PIP=100%).

339

340 **Drug repurposing.** Independent genetic signals from the cross-ancestry meta-analysis were
341 searched in OpenTargets.org[39] for druggability and medication target status based on nearest
342 genes. Among them, *OPRM1* implicated naltrexone and *GABRA4* implicated acamprosate, both
343 current treatments for AUD. Additionally, the genes *DRD2*, *CACNA1C*, *DPYD*, *PDE4B*, *KLB*,
344 *BRD3*, *NCAM1*, *FTOP*, and *MAPT*, were identified as druggable genes.

345

346 From the drug repurposing analysis using S-PrediXcan results, 287 compounds were
347 significantly correlated with the transcriptional pattern associated with risk for PAU
348 (Supplementary Table 14). Of these 287, 141 medications were anti-correlated with the
349 transcriptional pattern. Of those, trichostatin-a (p=3.29×10^{-35}), melperone (p=6.88×10^{-11}),
350 triflupromazine (p=7.37×10^{-10}), spironolactone (p=2.45×10^{-9}), amlodipine (p=1.42×10^{-6}) and
351 clomethiazole (p=1.30×10^{-5}) reversed the transcriptional profile associated with increased PAU
352 risk, targeted a gene near an independent significant locus in the cross-ancestry GWAS.

353

354 **Cross-ancestry polygenic risk score association.** We tested the cross-ancestry PRS
355 association with AUDIT-P in UKB using AUD summary data from EUR (leaving out the UKB
356 AUDIT-P data), AFR, and LA. PRS-CSx was applied to calculate the posterior effect sizes for
357 each SNP by leveraging LD diversity across discovery samples[40]. We validated the PRS
358 associations with AUDIT-P in UKB-EUR2 and tested them in UKB-EUR1 (see Table 1). In the
359 UKB-EUR1 samples, EUR-based AUD PRS is significantly associated with AUDIT-P (Z-

score=11.6, p=3.14×10^{-31}, ΔR^2=0.11%). By incorporating GWAS data from multiple ancestries, the AUD PRS is more significantly associated with AUDIT-P and explains more variance (Z-score=13.6, p=2.44×10^{-42}, ΔR^2=0.15%) than the single ancestry AUD PRS.

Genetic correlations. We confirmed significant positive genetic correlations (r_g) in EUR between PAU and substance use and psychiatric traits[6] (Supplementary Table 15). AD[5] showed the highest correlation with PAU (r_g=0.85, SE=0.07, p=4.49×10^{-34}), followed by maximum habitual alcohol intake[9] (r_g=0.79, SE=0.03, p=1.24×10^{-191}), opioid use disorder[41] (r_g=0.78, SE=0.04, p=1.20×10^{-111}), drinks per week[11] (r_g=0.76, SE=0.02, p<1×10^{-200}), smoking trajectory[42] (r_g=0.63, SE=0.02, p=2.47×10^{-176}), and cannabis use disorder[14] (r_g=0.61, SE=0.04, p=4.85×10^{-63}). We next tested r_g between AUD and 13 published traits with large GWAS in AFR (Figure 3, Supplementary Table 16). As in EUR, the traits with the strongest correlations were substance use traits. Maximum habitual alcohol intake[9] (r_g=0.67, SE=0.15, p=8.13×10^{-6}) showed the highest correlation with AUD, followed by opioid use disorder[41] (r_g=0.62, SE=0.10, p=6.70×10^{-10}), and smoking trajectory[42] (r_g=0.57, SE=0.08, p=3.64×10^{-4}). Major depressive disorder[43] and smoking initiation[11] showed nominally significant (p<0.05) positive correlation with AUD and type 2 diabetes[44] showed a nominally significant negative correlation.

Figure 3. Genetic correlations between AUD and traits in AFR. totalPCL, total index of recent symptom severity by PTSD checklist for DSM-IV. Traits labeled in bold font are genetically correlated with AUD after Bonferroni correction (p<3.83×10^{-3}). Error bar is 95% confidence interval.

Traits	Study	N	p
Maximum habitual alcohol intake	Deak, 2022	29,132	**8.13×10^{-6}**
Opioid use disorder	Kember, 2022	88,497	**6.70×10^{-10}**
Smoking trajectory	Xu, 2020	54,867	**3.64×10^{-13}**
Post-traumatic stress disorder	Stein, 2021	51,036	0.45
avoidance		25,414	0.27
totalPCL		25,318	0.24
reexperiencing		25,414	0.18
hyperarousal		25,521	0.45
Cigarettes per day	Saunders, 2022	20,157	0.40
Smoking initiation	Saunders, 2022	119,589	0.02
Major depressive disorder	Levey, 2021	85,083	0.02
Type II diabetes	Vujkovic, 2020	76,750	0.01



PRS for phenome-wide associations. We calculated PRS for PAU (based on the meta-analysis of PAU in EUR) in 131,500 individuals of European ancestry, PRS for AUD (based on the meta-analysis of AUD in AFR) in 27,494 individuals of African ancestry in 4 biobanks (Vanderbilt University Medical Center BioVU, Penn Medicine BioBank, Mount Sinai Icahn School of Medicine Bio*Me* ™, and Mass General Brigham Biobank) from the PsycheMERGE Network, and conducted phenome-wide association studies (PheWAS). After Bonferroni correction, 58 of the 1,493 tested phenotypes were significantly associated with the PAU PRS in EUR, including 26 mental disorders, 8 respiratory traits, 5 neurological conditions, 4 infectious diseases, and 4 neoplasms (Supplementary Table 17, Supplementary Figure 2). For the 793 phenotypes tested in AFR, alcoholism (OR=1.25, SE=0.04, $p=2.62\times10^{-7}$), alcohol-related disorders (OR=1.21, SE=0.04, $p=4.11\times10^{-7}$), and tobacco use disorder (OR=1.09, SE=0.02, $p=6.98\times10^{-6}$) showed significant association with AUD PRS (Supplementary Table 18, Supplementary Figure 3).

We also conducted PheWAS in Yale-Penn, a deeply phenotyped cohort with comprehensive psychiatric assessments (substance use disorders [SUDs] and psychiatric disorders) and assessments for physical and psychosocial traits[26,45]. In EUR, the PRS of PAU

401 was associated with 123 traits, including 26 in alcohol, 39 in opioid, 24 in cocaine and 17 in
402 tobacco categories (Supplementary Table 19, Supplementary Figure 4), indicating high
403 comorbidity and shared genetic components across SUDs. In AFR, the AUD PRS was
404 associated with the DSM-5 AUD criterion count, alcohol-induced blackouts, frequency of alcohol
405 use, and 3 individual AUD criteria: unsuccessful effort to decrease use, used more than
406 intended, and continued use despite social/interpersonal problems (Supplementary Table 20,
407 Supplementary Figure 5).

408

409 **Discussion**

410 We report here the largest multi-ancestry GWAS for PAU to date, comprising over 1
411 million individuals and including 165,952 AUD/AD cases, more than double the largest previous
412 study[28]. Considering the results from this study and previous GWAS, in all ancestral populations,
413 we observed a nearly linear relationship between sample size and the number of risk variants
414 discovered.

415 Convergent evidence supports substantial shared genetic architecture for PAU across
416 multiple ancestries. First, of the 76 independent risk variants detected in EUR and represented
417 in other populations, the majority have the same direction of effect in AFR (84.2%) and LA
418 (81.6%). Twenty-three variants (30.3%) in AFR and 15 (19.7%) in LA were nominally replicated
419 (p<=0.05), which is considerable given the appreciably lower sample size of these ancestral
420 groups. Second, there are high cross-ancestry genetic correlations among EUR, AFR, and LA,
421 ranging from 0.71 (between EUR and AFR) to 0.88 (between AFR and LA). Third, cross-
422 ancestry meta-analysis substantially improved the power for gene discovery and resulted in the
423 identification of 24 additional variants beyond the EUR-only results.

424

425 A total of 110 variants were associated with PAU in either within-ancestry or cross-
426 ancestry analyses; of these, 9 are missense variants. These include rs1799971 in *OPRM1*
427 which encodes the *μ* opioid receptor, which plays roles in regulating pain, reward, and addictive
428 behaviors. This variant was also associated with opioid use disorder (OUD) in multiple large
429 GWAS[41,46,47]. Previously, there were inconsistent candidate gene association results for
430 *OPRM1**rs1799971 and AUD (reviewed in ref. 48). This is the first GWAS to confirm the
431 association of rs1799971 in PAU; the risk allele is the same as for OUD. In contrast to an
432 apparent EUR-specific effect of rs1799971 on OUD, the *OPRM1* association with PAU
433 (p=6.16×10^{-9}) was detected in the cross-ancestry meta-analysis. Further investigation in larger
434 non-EUR samples is needed to assess the association of this SNP with SUDs in different
435 population groups. Rs6265 in *BDNF* (brain-derived neurotrophic factor) encodes a member of
436 the nerve growth factor family of proteins and has been investigated intensively in the past
437 decades[49]; studies showed that this variant is associated with smoking traits[10] and externalizing
438 behavior[50]. Rs13107325 in *SLC39A8* (Solute Carrier Family 39 Member 8) has been associated
439 with schizophrenia[51], substance uses[6,7,10] and many glycemic traits, and is critical for
440 glycosylation pathways[52,53].

441

442 Previous studies have shown that PAU is a brain-related trait with evidence of functional
443 and heritability enrichment in multiple brain regions[6,7]. We performed gene-based association,
444 TWAS in brain tissues, and H-MAGMA analysis in brain annotations. We identified 38 genes
445 that were supported across multiple levels of analysis. For example, *ADH1B* expression in
446 putamen was associated with PAU by TWAS, and with chromatin interaction in all 6 brain
447 annotations by H-MAGMA, indicating additional potential biological mechanisms for the
448 association of *ADH1B* with PAU risk through gene expression and/or chromatin interactions in
449 brain, potentially independent of the well-known hepatic effect on alcohol metabolism. *DRD2*

450 expression in cerebellar hemisphere and chromatin interaction in all brain annotations were also
451 associated with PAU risk. Alcohol metabolism, as is well-reported, has affects that modulate
452 alcohol's aversive and reinforcing effects[54], but also contributes to brain histone acetylation,
453 gene expression and alcohol-related associative learning in mice[55]. The detailed molecular
454 pathways and mechanisms involving changes in human brain need to be elucidated.

455

456 Independent genetic signals supported the two main AUD pharmacological treatments
457 acamprosate and naltrexone: *GABRA4* is a target of acamprosate while *OPRM1* is a target for
458 naltrexone. We identified genes known to be druggable; our multivariate analysis also provided
459 evidence for several repurposable drugs. Trichostatin-a, a histone deacetylase inhibitor, showed
460 effects on H3 and H4 acetylation and neuropeptide Y expression in the amygdala and
461 prevented the development of alcohol withdrawal-related anxiety in rats[56]. Clinical trials showed
462 that melperone, a dopamine and serotonin receptor antagonist, has inconsistent effects on
463 alcoholic craving[57,58]. Spironolactone, a mineralocorticoid receptor antagonist, reduced alcohol
464 use in both rats and humans in a recent study[59]. Clomethiazole, a GABA receptor antagonist,
465 also showed effect of treatment for alcohol withdrawal syndrome[60]. Future clinical trials may use
466 the evidence from this drug-repurposing analysis to prioritize drugs for further study.

467

468 PAU was positively genetically correlated with many psychiatric and substance use
469 disorders and negatively with cognitive performance. Most of our genetic correlations with PAU,
470 and all those in previous studies, were restricted to EUR populations, presumably because of
471 insufficient statistical power in other populations. The PheWAS PRS also identified associations
472 with medical phenotypes in EUR. With increasing number of AFR GWAS now published, mainly
473 from MVP, we were able to estimate genetic correlations between AUD and a limited set of

474 traits in AFR. As in EUR, AUD in AFR was genetically correlated with substance use traits
475 including OUD, smoking trajectory (which identifies groups of individuals that follow a similar
476 progression of smoking behavior), and maximum habitual alcohol intake. PheWAS of PRS in
477 AFR from PsycheMERGE and Yale-Penn confirmed that AUD is genetically correlated with
478 substance use traits. The lack of a wider set of phenotypes for comparison by ancestry is a
479 continuing limitation.

480

481 Additional limitations include that the differences in ascertainment and phenotypic
482 heterogeneity across cohorts might bias the results. Despite the high genetic correlation
483 between AUD and AUDIT-P, they are not identical traits. Also, differences in ascertainment
484 amongst the cohorts may have introduced additional biases; for example, considering the QIMR
485 AGDS and GBP cohorts, the former have high major depression comorbidity, and the latter
486 have high bipolar disorder comorbidity. (This heterogeneity would, however, have been more
487 likely to limit discovery than to create false-positives.) Additionally, while we set out to include all
488 available samples for problematic drinking in multiple ancestries, the sample sizes in the non-
489 EUR ancestries were still small for gene discoveries and downstream analyses. The collection
490 of substantial numbers of non-European subjects is a critical next step in this field.

491

492 In summary, we report here a large multi-ancestry GWAS and meta-analysis for PAU, in
493 which we focused our analyses in three main directions. First, we demonstrated that there is
494 substantial shared genetic architecture of PAU across multiple populations. Second, we
495 analyzed gene prioritization for PAU using multiple approaches, including cross-ancestry fine-
496 mapping, gene-based association, brain-tissue TWAS and fine-mapping, and H-MAGMA for
497 chromatin interaction. We identified many genes associated with PAU with biological support,

498 extending our understanding of the brain biology that substantially modifies PAU risk and
499 expands opportunities for investigation using *in vitro* methods and animal models. These genes
500 are potential actionable targets for downstream functional studies and possible targets of
501 pharmacological intervention based on the drug repurposing results. Third, we investigated the
502 genetic relationship between PAU and many traits, which for the first time was possible in AFR
503 populations. Future increases in sample size will doubtless yield additional gains; this is
504 particularly needed in non-EUR populations both for primary GWAS analyses and the analysis
505 of other traits for comparison and to estimate pleiotropy.

506

507 **Methods**

508 **Study design.** In the previous PAU study[6], the r_g between MVP AUD and PGC alcohol
509 dependence (AD) was 0.98, which justified the meta-analysis of AUD (includes AUD and AD)
510 across the two datasets; and the r_g between AUD and UKB AUDIT-P was 0.71, which justified
511 the proxy-phenotype meta-analysis of PAU (including AUD, AD and AUDIT-P) across all
512 datasets. In this study, we use the same definitions, defining AUD by meta-analyzing AUD and
513 AD across all datasets, and defining PAU by meta-analyzing AUD, AD and AUDIT-P (Table 1).

514

515 **MVP dataset.** MVP enrollment and genotyping have been described previously[19,61]. MVP is a
516 biobank supported by the US Department of Veterans Affairs (VA) with rich phenotypic data
517 collected using questionnaires and the VA electronic health record system (EHR). The Central
518 VA Institutional Review Board (IRB) and site-specific IRBs approved the MVP study. All relevant
519 ethical regulations for work with human subjects were followed in the conduct of the study and
520 informed consent was obtained from all participants.

521

522 MVP genotype data were processed by the MVP Release 4 (R4) Data Team. 729,324
523 samples were genotyped using Affymetrix Axiom Biobank Array. Rigorous sample-level quality
524 control (QC) served to remove samples with duplicates, call rates <98.5%, sex mismatches, >7
525 relatives, or excess heterozygosity. After QC, MVP R4 data contains 658,582 participants and
526 667,995 variants (pre-imputation). Pre-imputation QC removed variants with high missingness
527 (>1.5%), that were monomorphic, or with Hardy-Weinberg Equilibrium (HWE) p-value $\leq 1\times10^{-6}$,
528 leaving 590,511 variants for imputation. As in our previous work[7], we ran principal component
529 analysis (PCA)[62,63] for the R4 data and 1000 Genome phase3 reference panels[64]. The
530 Euclidean distances between each MVP participant and the centers of the five reference
531 ancestral groups were calculated using the first 10 PCs, with each participant assigned to the
532 nearest reference ancestry. A second round PCA within each assigned ancestral group was
533 performed and outliers with PC scores >6 standard deviations from the mean of any of the 10
534 PCs were removed. This two-stage approach resulted in the assignment of 468,869 European
535 ancestry (EUR), 122,024 African ancestry (AFR), 41,662 Latin American (LA), 7,364 East Asian
536 (EAS) and 536 South Asian (SAS) individuals for analysis.

537

538 Imputation was done by the MVP R4 Data Team. The entire cohort was pre-phased
539 using SHAPEIT4 (v4.1.3)[65], then imputed using Minimac4[66] with African Genome Resources
540 reference panel by Sanger Institute and 1000 Genomes Project phase3 as reference. Single
541 nucleotide variants with imputation score <0.8, or HWE p-value $\leq 1\times10^{-6}$, or minor allele
542 frequency (MAF) lower than the threshold set in each ancestral group based upon their sample
543 size (EA, 0.0005; AA, 0.001; LA, 0.005; EAA, 0.01; SAA, 0.01) were removed before
544 association analysis.

545

546 Participants with at least one inpatient or two outpatient International Classification of
547 Diseases (ICD)-9/10 codes for AUD were assigned as AUD cases, while participants with zero
548 ICD codes for AUD were controls. Those with one outpatient diagnosis were excluded from the
549 analysis. In total, 80,028; 36,330; 10,150; 701; and 107 cases were included in EUR, AFR, LA,
550 EAS, and SAS, respectively; 368,113; 79,100; 28,812; 6,254; and 389 controls were included in
551 EUR, AFR, LA, EAS, and SAS, respectively. BOLT-LMM[67] was used to correct for relatedness,
552 with age, sex, and the first 10 PCs as covariates.

553

554 **UK Biobank (UKB).** UKB released genotype and imputed data for ~500,000 individuals from
555 across the United Kingdom[17] which were accessed through application 41910. UKB defined
556 White-British (WB) participants genetically. For the non-WB individuals, we used PCA to classify
557 them into different genetic groups as for MVP. Subjects with available AUDIT-P score were
558 included in this study. The final sample included 132,001 WB (hereafter called UKB-EUR1) and
559 17,898 non-WB Europeans (hereafter called UKB-EUR2), and 1,220 SAS. SNPs with genotype
560 call rate >0.95, HWE p-value $>1\times10^{-6}$, imputation score ≥0.8 and MAF ≥0.001 in EUR1 and
561 EUR2 and ≥0.01 in SAS were kept for GWAS, BOLT-LMM was used for association correcting
562 for relatedness, age, sex, and the first 10 PCs.

563

564 **FinnGen.** Summary statistics for AUD from FinnGen data freeze 5 were downloaded from the
565 FinnGen website (http://r5.finngen.fi/). Details of the genotyping, imputation and quality control
566 for FinnGen data were described previously[20]. There were 8,866 AUD cases defined by ICD-
567 8/9/10 codes and 209,926 controls. Association analysis was performed using SAIGE[68] mixed-
568 model with age, sex and 10 PCs as covariates. Positions of the variants were lifted over to build
569 37 (GRCh37/hg19) for meta-analysis.

570

571 **iPSYCH:** The iPSYCH[21,22] samples were selected from a baseline birth cohort comprising all
572 singletons born in Denmark between May 1, 1981, and December 31, 2008. The iPSYCH study
573 was approved by the Scientific Ethics Committee in the Central Denmark Region (Case No 1-
574 10-72-287-12) and the Danish Data Protection Agency.

575

576 AUD was diagnosed according to the ICD-10 criteria (F10.1 – F10.9 diagnosis codes).
577 The iPSYCH cohort was established to investigate genetic risk for major psychiatric disorders
578 (i.e., attention-deficit/hyperactivity disorder, schizophrenia, bipolar disorder, major depressive
579 disorder, autism spectrum disorder) but not AUD (or PAU), so comorbidity of psychiatric
580 disorders among these AUD cases is higher than expected for cases selected randomly from
581 the population. Therefore, we generated a control group around five times as large as the case
582 groups, and to correct for the bias introduced by high comorbidity of psychiatric disorders
583 among cases, we included within the control group individuals with the above listed psychiatric
584 disorders (without comorbid AUD) at a proportion equal to what was observed among the cases.

585

586 The samples were genotyped in two genotyping rounds referred to as iPSYCH1 and
587 iPSYCH2. iPSYCH1 samples were genotyped using Illumina's PsychChip array and iPSYCH2
588 samples using Illumina´s GSA v.2 (Illumina, San Diego, CA, USA). Quality control and GWAS
589 were performed using the Ricopili pipeline[69]. More details can be found in ref. 70. GWAS were
590 performed separately for iPSYCH1 (2,117 cases and 13,238 controls) and iPSYCH2 (1,024
591 cases and 5,732 controls) using dosages for imputed genotypes and additive logistic regression
592 with the first 5 PCs (from the final PCAs) as covariates using PLINK v1.9[71]. Only variants with a
593 MAF >0.01 and imputation score >0.8 were included in the final summary statistics.

594

595 **Queensland Berghofer Medical Research Institute (QIMR) cohorts.** The Australian Genetics
596 of Depression Study (AGDS) recruited >20,000 participants with major depression between
597 2017 and 2020. Recruitment and subject characteristics have been reported[24]: Participants
598 completed an online self-report questionnaire. Lifetime AUD was assessed on DSM-5 criteria
599 using the Composite International Diagnostic Interview (CIDI). A total of 6,726 subjects with and
600 4,467 without AUD were included in the present study.

601

602 The Australian twin-family study of alcohol use disorder (TWINS, including Australian
603 Alcohol and Nicotine Studies) participants were recruited from adult twins and their relatives
604 who had participated in questionnaire- and interview-based studies on alcohol and nicotine use
605 and alcohol-related events or symptoms (as described in Heath et al.[72]). They were
606 predominantly of EUR ancestry. Young adult twins and their non-twin siblings were participants
607 in the Nineteen and Up study (19Up)[25]. 2,772 cases and 5,630 controls were defined using
608 DSM-III-R and DSM-IV criteria. Most alcohol-dependent cases were mild, with 70% of those
609 meeting alcohol dependence criteria reporting only three or four dependence symptoms and ≤5%
610 reporting seven dependence symptoms.

611

612 The Australian Genetics of Bipolar Disorder Study (GBP) recruited >5,000 participants
613 living with bipolar disorder between 2018 and 2021. The sample's recruitment and
614 characteristics have been reported[23]: Participants completed an online self-report questionnaire.
615 Lifetime DSM-5 AUD was assessed using the CIDI.

616

617 Genotyping of QIMR cohorts was performed using Illumina Global Screening Array v2.
618 Pre-imputation QC removed variants with GenTrain score <0.6, MAF <0.01, SNP call rate <95%,
619 and Hardy-Weinberg equilibrium deviation ($p<1x10^{-6}$). Variants were then imputed using the
620 Michigan Imputation Server with the Haplotype Reference Consortium reference panel[66].
621 Association analysis was performed using SAIGE and the LOCO=TRUE flag with age, sex, 10
622 PCs and two imputation variables as covariates. Participants of non-EUR ancestry (defined
623 as >6 standard deviations from the PC1 and PC2 centroids) were excluded. Association
624 analyses were limited to variants with a MAF≥0.0001, MAC≥5, and an R^2≥0.1.

625

626 **Psychiatric Genomics Consortium (PGC).** Lifetime DSM-IV diagnosis of AD in both EUR and
627 AFR ancestries were analyzed by PGC, with details reported previously[5]. This included 5,638
628 individuals from Australia. To avoid overlap with the new QIMR cohorts, we re-analyzed the
629 PGC data without two Australian cohorts: Australian Alcohol and Nicotine Studies and Brisbane
630 Longitudinal Twin Study. This yielded 9,938 cases and 30,992 controls of EUR ancestry and
631 3,335 cases and 2,945 controls of AFR ancestry.

632

633 **Yale-Penn 3.** There are 3 phases of the Yale-Penn study defined by genotyping epoch; the first
634 two were incorporated in the PGC study, thus they are included in the meta-analyses. Here, we
635 included Yale-Penn 3 subjects as a separate sample. Lifetime AD was diagnosed based on
636 DSM-IV criteria. Genotyping was performed in the Gelernter laboratory at Yale using the
637 Illumina Multi-Ethnic Global Array, then imputed using Michigan Imputation Server with
638 Haplotype Reference Consortium reference. We did PCA analyses to classify EAs (567 cases
639 and 1,074 controls) and AAs (451 cases and 410 controls). Variants with MAF >0.01, HWE p-
640 value $>1\times10^{-6}$ and imputation INFO score ≥0.8 were retained for association analyses using

641 linear mixed models implemented in GEMMA[73] and corrected for age, sex and 10 PCs.

642

643 **East Asian cohorts.** Summary statistics for AUD/AD GWAS from 5 EAS cohorts (MVP EAS,
644 Han Chinese–GSA, Thai METH–MEGA, Thai METH–GSA and Han Chinese–Cyto) were
645 included in the cross-ancestry meta-analysis. Analyses of these five cohorts were previously
646 published and the detailed QC can be found in ref. 27.

647

648 **Meta-analyses.** Meta-analyses were performed using METAL[74] with effective sample size
649 weighting. For all the case-control samples, we calculated effective sample size as:

650
$$n_{effective} = \frac{4}{\frac{1}{n_{case}} + \frac{1}{n_{control}}}$$

651 For AUDIT-P in UKB, a continuous trait, we used actual sample sizes for meta-analysis. For all
652 meta-analyses within or across ancestries, variants with a heterogeneity test p-value $<5\times10^{-8}$
653 and variants with effective sample size <15% of the total effective sample size were removed.
654 For the cross-ancestry and EUR within-ancestry meta-analyses, we required that variants were
655 present in at least two cohorts. For the AFR and SAS within-ancestry meta-analyses, which are
656 small samples, this was not required.

657

658 **Independent variants and conditional analyses.** We identified the lead variants using PLINK
659 with parameters of clumping region 500 kb and LD r^2 0.1. We then ran conditional analyses
660 using GCTA-COJO[75] to define conditionally independent variants among the lead variants using
661 the 1000 Genomes Project phase3 as the LD reference panel. Any two independent variants <1
662 Mb apart whose clumped regions overlapped were merged into one locus.

663

664 **Cross-ancestry lookup.** For the 85 independent variants associated in EUR, we looked up the
665 associations in non-EUR groups. If the variants were not observed in another ancestry, we
666 substituted proxy SNPs defined as associated with PAU ($p<5\times10^{-8}$) and in high LD with the EUR
667 lead SNP ($r^2\geq0.8$).

668

669 **SNP-based heritability (h^2).** SNP-based h^2 for common SNPs mapped to HapMap3[76] was
670 estimated in EUR, AFR and LA ancestries using LDSC[77]; corresponding populations in the 1000
671 Genomes Project phase3 were used as LD reference panels. For PAU in EUR, we only
672 estimated the observed-scale h^2. For AUD, both observed-scale h^2 and liability-scale h^2 were
673 estimated, using population lifetime prevalence estimates of 0.326, 0.220, and 0.229 in EUR,
674 AFR, and LA, respectively[1]. These prevalence estimates were for lifetime DSM-5 AUD in the
675 United States, which could introduce bias given the different definitions and prevalence in
676 different cohorts. By default, LDSC removes SNPs with sample size <90th percentile N/2. Here
677 we skipped this filtering and kept all SNPs for analyses because we did basic filtering based on
678 the number of cohorts and sample size. The final number of SNPs in the analyses range from
679 527,994 to 1.17 M.

680

681 **Cross-ancestry genetic correlation.** We estimated the genetic correlations between different
682 ancestries using Popcorn[78], which can estimate both the genetic-effect correlation (ρ_{ge}) as
683 correlation coefficient of the per-allele SNP effect sizes and the genetic-impact correlation (ρ_{gi})
684 as correlation coefficient of the ancestry-specific allele-variance-normalized SNP effect sizes.
685 Populations in 1000 Genomes were used as reference for their corresponding population. A
686 large sample size and number of SNPs are required for accurate estimation[78], which explains

687 the non-robust estimates for EAS and SAS samples.

688

689 **Within- and cross-ancestry fine-mapping.** We did fine-mapping using MsCAVIAR[79], which
690 can leverage LD information from multiple ancestries to improve fine-mapping of causal variants.
691 To reduce bias introduced by populations with small sample size, here we performed fine-
692 mapping using summary statistics from the EUR, AFR and LA populations. Three sets of
693 analyses were conducted. The first is within-ancestry fine-mapping for the 85 regions with
694 independent variants in EUR using EUR summary data and 1000 Genomes Project phase3
695 EUR LD reference data. For each region, we selected SNPs which clumped (within 500 kb and
696 LD r^2>0.1) with the lead SNP and with p<0.05 for fine-mapping. We then calculated the pair-
697 wise LD among the selected SNPs. If two SNPs were in perfect LD (r^2=1, indicating that they
698 are likely to be inherited together), we randomly removed one from the analysis. The second is
699 cross-ancestry fine-mapping for the 100 regions with independent variants identified in cross-
700 ancestry meta-analyses. For each region, we performed clumping (within 500 kb and LD r^2>0.1)
701 in EUR, AFR, and LA summary data for the lead SNP separately, to select 3 sets of SNPs
702 (p<0.05) for fine-mapping, corresponding LD reference panels from 1000 Genomes Project
703 were used. For each set of SNPs, we calculated the pair-wise LD and randomly removed one
704 SNP if r^2=1. If the lead SNP was not presented in the EUR SNP set, we did not perform fine-
705 mapping for this region. Loci with limited numbers of variants cannot have convergent results,
706 so they are not included in the results. After that, this cross-ancestry analysis included 92
707 regions. For the 10 regions in which the lead SNPs are missing in both AFR and LA populations,
708 we did within-ancestry fine-mapping in EUR instead to keep the lead SNP (cross-ancestry fine-
709 mapping will only analyze the SNPs common in analyzed ancestries). Third, because the
710 credible set length identified is related to the number of variants in the input, to provide a more
711 direct comparison between the cross-ancestry fine-mapping and the fine-mapping using

712 information only from EUR, we used the same lists of SNPs from the above 92 regions in the
713 cross-ancestry fine-mapping as for the EUR-only fine-mapping. “Credible set” was defined as
714 plausible causal variants with accumulated posterior inclusion probability (PIP) > 99%. For each
715 credible set, we report the variant with the highest PIP. We assumed that each locus contains
716 only one causal variant by default, and increased to three at maximum if the analysis unable to
717 converge.

718

719 **Gene-based association analyses.** We performed gene-based association analysis for PAU
720 or AUD in multiple ancestries using MAGMA implemented in FUMA[32,33]. Default settings were
721 applied. Bonferroni corrections for the number of genes tested (range from 18,390 to 19,002 in
722 different ancestries) were used to determine genome-wide significant genes.

723

724 **Transcriptome-wide association study (TWAS).** For PAU in EUR, we performed TWAS using
725 S-PrediXcan to integrate transcriptomic data from GTEx. With prior knowledge that PAU is a
726 brain-related disorder (evidenced by significant enrichment of gene expression in several brain
727 tissues)[6], 13 brain tissues were analyzed. The transcriptome prediction model database and the
728 covariance matrices of the SNPs within each gene model were downloaded from the PredictDB
729 repository (http://predictdb.org/). Significance of the gene-tissue association was determined
730 following Bonferroni correction for the total number of gene-tissue pairs
731 (p<0.05/166,064=3.01×10^{-7}). We also used S-MultiXcan[36] to integrate evidence across the 13
732 brain tissues using multivariate regression to improve association detection. In total, 18,383
733 genes were tested in S-MultiXcan, leading to a significance p-value threshold of 2.72×10^{-6}.

734

735 **Association with chromatin interactions in brain.** We used H-MAGMA[37], a computational

736 tool that incorporates brain chromatin interaction profiles from Hi-C, to identify risk genes
737 associated with PAU based on EUR inputs. Six brain annotations were used: fetal brain, adult
738 brain, adult midbrain dopaminergic, iPSC-derived astrocyte, iPSC-derived neuron and cortical
739 neuron. In total, 319,903 gene-chromatin associations were analyzed across the six brain
740 annotations. Significant genes were those with a p-value below the Bonferroni corrected value
741 for the total number of tests (p<0.05/319,903=1.56×10^{-7}).

742

743 **Probabilistic fine-mapping of TWAS.** We did fine-mapping for TWAS in EUR using FOCUS[38],
744 a method that models correlation among TWAS signals to assign a PIP for every gene in the
745 risk region to explain the observed association signal. The estimated credible set containing the
746 causal gene can be prioritized for functional assays. FOCUS used 1000 Genomes Project EUR
747 samples as the LD reference and multiple eQTL reference panel weights that include
748 GTEx_v7[80], The Metabolic Syndrome in Men[81], Netherlands Twin Register[82], Young Finns
749 Study[83], and CommonMind Consortium[84]. Under the model of PAU as substantially a brain
750 disorder, we did fine-mapping while prioritizing predictive models using a brain tissue-prioritized
751 approach.

752

753 **Drug repurposing.** To match inferred transcriptional patterns of PAU with transcriptional
754 patterns induced by perturbagens, we related our S-PrediXcan results to signatures from the
755 Library of Integrated Network-based Cellular Signatures (LINCs) L1000 database[85]. This
756 database catalogues *in vitro* gene expression profiles (signatures) from thousands of
757 compounds >80 human cell lines (level 5 data from phase I: GSE92742 and phase II:
758 GSE70138). Our analyses included signatures of 829 chemical compounds in five neuronal cell-
759 lines (NEU, NPC, MNEU.E, NPC.CAS9 and NPC.TAK). To test significance of the association

760 between PAU signatures and LINCs perturbagen signatures we followed the procedure from So
761 et al[86]. Briefly, we computed weighted (by proportion of heritability explained) Pearson
762 correlations between transcriptome-wide brain associations and *in vitro* L1000 compound
763 signatures using the *metafor* package[87] in R. We treated each L1000 compound as a fixed
764 effect incorporating the effect size ($r_{weighted}$) and sampling variability (se^2) from all signatures of a
765 compound (e.g., across all time points and doses). We only report those perturbagens that were
766 associated after Bonferroni correction ($p<0.05/829=6.03\times10^{-5}$).

767

768 **Cross-ancestry polygenic risk score.** We used PRS-CSx[40], a method that couples genetic
769 effects and LD across ancestries via a shared continuous shrinkage prior, to calculate the
770 posterior effect sizes for SNPs mapped to HapMap3. Three sets of AUD GWAS summary data
771 were use as input and corresponding posterior effect sizes in each ancestry were generated:
772 EUR (without AUDIT-P from UKB, $N_{effective}$=352,373), AFR ($N_{effective}$=105,433), and LA
773 ($N_{effective}$=30,023). Three sets of AUD PRS based on the posterior effect sizes were calculated
774 for UKB-EUR1 and UKB-EUR2 individuals using PLINK, following standardization (zero mean
775 and unit variance) for each PRS. For each related pair (≥3rd-degree, kinship coefficient ≥0.0442
776 as calculated by UKB), we removed the subject with the lower AUDIT-P score, or randomly if
777 they had the same score, leaving 123,565 individuals in UKB-EUR1 and 17,401 in UKB-EUR2.
778 Then we ran linear regression for AUDIT-P in UKB-EUR2 as a validation dataset using PRS_{EUR},
779 PRS_{AFR} and PRS_{LA} as independent variables. The corresponding regression coefficients were
780 used as weights in the test dataset (UKB-EUR1) to calculate the final PRS: PRS_{final} =
781 $\omega_{EUR}*PRS_{EUR} + \omega_{AFR}*PRS_{AFR} + \omega_{LA}*PRS_{LA}$. We used linear regression to test the association
782 between AUDIT-P and PRS_{final} after standardization, correcting for age, sex, and the first 10
783 PCs. We also ran a null model of association between AUDIT-P and covariates only, to
784 calculate the variance explained (R^2) by PRS_{final}. For comparison, we also calculated PRS in

785 UKB-EUR1 using only the AUD summary data in EUR using PRS-CS[88], then calculated the
786 variance explained by PRS_{single}. The improved PRS association was measured as the difference
787 of the variance explained (ΔR^2).

788

789 **Genetic correlation.** Genetic correlations (r_g) between PAU or AUD and traits of interest were
790 estimated using LDSC[89]. For EUR, we tested r_g between PAU and 49 traits using published
791 summary data and the EUR LD reference from the 1000 Genomes Project. r_gs with p-value
792 $<1.02\times10^{-3}$ were considered significant. For AFR, we tested r_g between AUD and 13 published
793 traits in AFR using MVP in-sample LD (most of the analyzed AFR were from MVP) built from
794 1000 randomly-selected AFR subjects by cov-LDSC[90]. r_gs with p-value $<3.85\times10^{-3}$ (0.05/13) in
795 AFR were considered as significant. For comparison, we also tested r_gs using 1000 Genomes
796 AFR as LD reference, which showed similar estimates.

797

798 **PAU PRS for phenome-wide associations.**

799 We calculated PRS using PRS-continuous shrinkage (PRS-CS) for PAU (in EUR) and AUD (in
800 AFR) in four independent datasets [Vanderbilt University Medical Center's Biobank (BioVU),
801 Mount Sinai (Bio*Me* ™), Mass General Brigham Biobank (MGBB)[91] and Penn Medicine Biobank
802 (PMBB)[92]] from the PsycheMERGE Network, followed by phenome-wide association studies.
803 Details for each dataset are described below.

804

805 ***BioVU***: Genotyping of individuals was performed using the Illumina MEGEX array. Genotypes
806 were filtered for SNP and individual call rates, sex discrepancies, and excessive heterozygosity
807 using PLINK. Imputation was conducted using the Michigan Imputation Server based on the

808 Haplotype Reference Consortium reference panel. PCA using FlashPCA2[93] combined with CEU,
809 YRI and CHB reference sets from the 1000 Genomes Project Phase 3 was conducted to
810 determine participants of AFR and EUR ancestry. One individual from each pair of related
811 individuals was removed (pi-hat>0.2). This resulted in 12,384 AFR and 66,903 EUR individuals
812 for analysis.

813

814 *BioMe ™*: The Bio*Me ™* Biobank: The Illumina Global Screening Array was used to genotype the
815 Bio*Me ™* samples. The SNP-level quality control (QC) removed SNPs with (1) MAF <0.0001 (2)
816 HWE p-value $\leq 1\times10^{-6}$ and (3) call rate <98%. The individual-level QC removed participants with
817 (1) sample call rate <98% and (2) heterozygosity F coefficient ≥3 standard deviations. In
818 addition, one individual from each pair of related samples with a genomic relatedness
819 (proportion IBD) >0.125 was removed (--rel-cutoff=0.125 in PLINK). Imputation was
820 performed using 1000 Genomes Phase 3 data. Each ancestry was confirmed by the genetic PC
821 plot. A final sample size of 4,727 AFR and 9,544 EUR individuals were included for this study.

822

823 ***MGBB***: Individuals in the Mass General Brigham Biobank (MGBB) were genotyped using the
824 Illumina Multi-Ethnic Global array with hg19 coordinates. Variant-level quality control filters
825 removed variants with a call rate <98% and those that were duplicated across batches,
826 monomorphic, not confidently mapped to a genomic location, or associated with genotyping
827 batch. Sample-level quality control filters removed individuals with a call rate less than 98%,
828 excessive autosomal heterozygosity (±3 standard deviations from the mean), or discrepant self-
829 reported and genetically inferred sex. PCs of ancestry were calculated in the 1000 Genomes
830 Phase 3 reference panel and subsequently projected onto the MGBB dataset, where a Random
831 Forest classifier was used to assign ancestral group membership for individuals with a

832 prediction probability >90%. The Michigan Imputation Server was then used to impute missing
833 genotypes with the Haplotype Reference Consortium dataset serving as the reference panel.
834 Imputed genotype dosages were converted to hard-call format and subjected to further quality
835 control, where SNPs were removed if they exhibited poor imputation quality (INFO<0.8), low
836 minor allele frequency (<1%), deviations from Hardy-Weinberg equilibrium ($p<1\times10^{-10}$), or
837 missingness (variant call rate <98%). Only unrelated individuals (pi-hat<0.2) of EUR ancestry
838 were included in the present study. These procedures yielded a final analytic sample of 25,698
839 individuals in the MGBB.

840

841 ***PMBB:*** Genotyping of individuals was performed using the Illumina Global Screening Array.
842 Quality control removed SNPs with marker call rate <95% and sample call rate <90%, and
843 individuals with sex discrepancies. Imputation was performed using Eagle2[94] and Minimac4 on
844 the TOPMed Imputation Server. One individual from each pair of related individuals (pi-hat
845 threshold of 0.25) were removed from analysis. PCA was conducted using smartpca[62,63] and the
846 Hapmap3 dataset to determine genetic ancestry. This resulted in 10,383 AFR and 29,355 EUR
847 individuals for analysis.

848

849 ***PheWAS:*** The AFR AUD PRS and EUR PAU PRS scores in each dataset were standardized
850 for the PheWAS analyses. International Classification of Diseases (ICD)-9 and -10 codes were
851 extracted from the electronic health record and mapped to phecodes. Individuals were
852 considered cases if they had two instances of the phecode. We conducted PheWAS by fitting a
853 logistic regression for each phecode within each biobank. Covariates included sex, age and the
854 top 10 PCs. PheWAS results were meta-analyzed within each ancestral group across biobanks
855 (AFR=27,494, EUR=131,500) using the PheWAS package[95] in R.

856

857 ***Yale-Penn***: Quality control and creation of the PheWAS dataset have been described
858 previously[45]. We calculated PRS for PAU in EUR and AUD in AFR (using summary statistics
859 that leave out the Yale-Penn 3 and PGC sample which includes Yale-Penn 1 and 2). We
860 conducted PheWAS by fitting logistic regression models for binary traits and linear regression
861 models for continuous traits. We used sex, age at recruitment, and the top 10 genetic PCs as
862 covariates. We applied a Bonferroni correction to control for multiple comparisons.

863

864 **Data Availability:** The full summary-level association data from the meta-analysis are available
865 upon request to the corresponding authors and through dbGaP (accession number phs001672).

866

867 **Acknowledgements**

868 This research used data from the Million Veteran Program and was supported by funding from
869 the Department of Veterans Affairs Office of Research and Development, Million Veteran
870 Program Grant #I01CX001849, #I01BX004820, #I01BX003341, and the VA Cooperative
871 Studies Program (CSP) study #575B, MVP004, and MVP025. This publication does not
872 represent the views of the Department of Veterans Affairs or the United States Government.
873 Supported also by NIH (NIAAA) P50 AA12870 (J.H.K.) and K01 AA028292 (R.L.K.), a NARSAD
874 Young Investigator Grant 27835 from the Brain & Behavior Research Foundation (H.Z.), NCI
875 R21 CA252916 (H.Z.), R01 AA026364 (J.G.), NIAAA T32 AA028259 (J.D.D.), NIMH R01
876 MH124839 (L.M.H.), NIAAA K01 AA030083 (A.S.H.), NIDA K01 DA051759 (E.C.J.), TRDRP
877 (T29KT0526, T32IR5226, S.S.R.) and NIDA DP1 DA054394 (S.S.R.). This research used data
878 from UK Biobank (project ID: 41910), a population-based sample of participants whose
879 contributions we gratefully acknowledge. The data access is supported by Yale SCORE pilot

880 grant (U54AA027989). We want to acknowledge the participants and investigators of the
881 FinnGen study. D.D. was supported by the Novo Nordisk Foundation (NNF20OC0065561), the
882 Lundbeck Foundation (R344-2020-1060). The iPSYCH team was supported by grants from the
883 Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003), NIH/NIMH
884 (1U01MH109514-01 and 1R01MH124851-01 to A.D.B.) and the Universities and University
885 Hospitals of Aarhus and Copenhagen. The Danish National Biobank resource was supported by
886 the Novo Nordisk Foundation. High-performance computer capacity for handling and statistical
887 analysis of iPSYCH data on the GenomeDK HPC facility was provided by the Center for
888 Genomics and Personalized Medicine and the Centre for Integrative Sequencing, iSEQ, Aarhus
889 University, Denmark (grant to A.D.B.). The Australian Genetics of Depression Study (AGDS)
890 was primarily funded by the National Health and Medical Research Council (NHMRC) of
891 Australia Grant No. 1086683 to N.G.M. N.G.M is supported by a NHMRC Investigator Grant (No.
892 APP 1172990). We are indebted to all of the participants for giving their time to contribute to this
893 study. We wish to thank all the people who helped in the conception, implementation, media
894 campaign and data cleaning. We thank Richard Parker, Simone Cross, and Lenore Sullivan for
895 their valuable work coordinating all the administrative and operational aspects of the AGDS
896 project. We would also like to thank the research participants for making this work possible. The
897 Australian Genetics of Bipolar Disorder Study (GBP) data collection was funded and data
898 analysis was supported by the Australian NHMRC (No. APP1138514) to S.E.M. S.E.M. is
899 supported by a NHMRC Investigator Grant (No. APP1172917). We thank the participants for
900 giving their time and support for this project. We acknowledge and thank M. Steffens for her
901 generous donations and fundraising support. The NHMRC (APP10499110) and the NIH
902 (K99R00, R00DA023549) funded the 19Up study. Genotyping was funded by the NHMRC
903 (389891). We thank the twins and their families for their willing participation in our studies.
904 Funding for the Australian adult twin studies in which information on alcohol use and smoking
905 status was obtained came from the US NIH (AA07535, AA07728, AA11998, AA13320,

906 AA13321, AA14041, AA17688, DA012854 and DA019951); the Australian NHMRC (241944,
907 339462, 389927, 389875, 389891, 389892, 389938, 442915, 442981, 496739, 552485 and
908 552498); and the Australian Research Council (A7960034, A79906588, A79801419,
909 DP0770096, DP0212016 and DP0343921). We acknowledge the work over many years of staff
910 of the Genetic Epidemiology group at QIMR Berghofer Medical Research Institute (formerly the
911 Queensland Institute of Medical Research) in managing the studies which generated the data
912 used in this analysis. We also acknowledge and appreciate the willingness of study participants
913 to complete multiple, and sometimes lengthy, questionnaires and interviews. Many of the
914 participants were contacted originally through the Australian Twin Registry. This research also
915 used summary data from the Psychiatric Genomics Consortium (PGC) Substance Use
916 Disorders (SUD) working group. The PGC-SUD is supported by NIH grant R01DA054869.
917 PGC-SUD gratefully acknowledges its contributing studies and the participants in those studies,
918 without whom this effort would not be possible. We acknowledge the Penn Medicine BioBank
919 (PMBB) for providing data and thank the patient-participants of Penn Medicine who consented
920 to participate in this research program. We would also like to thank the PMBB team and
921 Regeneron Genetics Center for providing genetic variant data for analysis. The PMBB is
922 approved under IRB protocol# 813913 and supported by Perelman School of Medicine at
923 University of Pennsylvania, a gift from the Smilow family, and the National Center for Advancing
924 Translational Sciences of the NIH under CTSA award number UL1TR001878. This study was
925 supported in part through the resources and staff expertise provided by the Charles Bronfman
926 Institute for Personalized Medicine and The Bio*Me*™ Biobank Program at the Icahn School of
927 Medicine at Mount Sinai. Research reported in this paper was supported by the Office of
928 Research Infrastructure of the NIH under award numbers S10OD018522 and S10OD026880.
929 The content is solely the responsibility of the authors and does not necessarily represent the
930 official views of the NIH.

931

932 Disclosure: H.R.K. is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne
933 Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the
934 recipient of research funding and medication supplies for an investigator-initiated study from
935 Alkermes; and a member of the American Society of Clinical Psychopharmacology's Alcohol
936 Clinical Trials Initiative, which was supported in the past 3 years by Alkermes, Dicerna,
937 Ethypharm, Lundbeck, Mitsubishi, Otsuka, and Pear Therapeutics. M.B.S. has in the past
938 3 years been a consultant for Actelion, Acadia Pharmaceuticals, Aptinyx, Bionomics, BioXcel
939 Therapeutics, Clexio, EmpowerPharm, Epivario, GW Pharmaceuticals, Janssen, Jazz
940 Pharmaceuticals, Roche/Genentech and Oxeia Biopharmaceuticals. M.B.S. has stock options in
941 Oxeia Biopharmaceuticals and Epivario. He also receives payment from the following entities for
942 editorial work: *Biological Psychiatry* (published by Elsevier), *Depression and Anxiety* (published
943 by Wiley) and *UpToDate*. J.G. and H.R.K. hold US patent 10,900,082 titled: "Genotype-guided
944 dosing of opioid agonists," issued January 26, 2021. J.G. is paid for his editorial work on the
945 journal *Complex Psychiatry*. J.H.K. has consulting agreements (less than US$10,000 per year)
946 with the following: AstraZeneca Pharmaceuticals, Biogen, Idec, MA, Biomedisyn Corporation,
947 Bionomics, Limited (Australia), Boehringer Ingelheim International, COMPASS Pathways,
948 Limited, United Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc.,
949 Heptares Therapeutics, Limited (UK), Janssen Research & Development, Otsuka America,
950 Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion
951 Pharmaceuticals, Inc., Takeda Industries and Taisho Pharmaceutical Co., Ltd. J.H.K. serves on
952 the scientific advisory boards of Bioasis Technologies, Inc., Biohaven Pharmaceuticals, BioXcel
953 Therapeutics, Inc. (Clinical Advisory Board), BlackThorn Therapeutics, Inc., Cadent
954 Therapeutics (Clinical Advisory Board), Cerevel Therapeutics, LLC., EpiVario, Inc., Lohocla
955 Research Corporation, PsychoGenics, Inc.; is on the board of directors of Inheris Biopharma,

956 Inc.; has stock options with Biohaven Pharmaceuticals Medical Sciences, BlackThorn
957 Therapeutics, Inc., EpiVario, Inc. and Terran Life Sciences; and is editor of *Biological Psychiatry*
958 with income greater than $10,000. I.B.H. is the Co-Director of Health and Policy at the Brain and
959 Mind Centre (BMC) University of Sydney. The BMC operates an early-intervention youth
960 services at Camperdown under contract to Headspace. He is the Chief Scientific Advisor to, and
961 a 3.2% equity shareholder in, InnoWell Pty Ltd. InnoWell was formed by the University of
962 Sydney (45% equity) and PwC (Australia; 45% equity) to deliver the $30 M Australian
963 Government-funded Project Synergy (2017-20; a three-year program for the transformation of
964 mental health services) and to lead transformation of mental health services internationally
965 through the use of innovative technologies. J.W.S. is a member of the Leon Levy Foundation
966 Neuroscience Advisory Board, the Scientific Advisory Board of Sensorium Therapeutics (with
967 equity), and has received grant support from Biogen, Inc. He is PI of a collaborative study of the
968 genetics of depression and bipolar disorder sponsored by 23andMe for which 23andMe
969 provides analysis time as in-kind support but no payments. All other authors report no
970 biomedical financial interests or potential conflicts of interest.

References

1. Grant, B.F., *et al.* Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. *JAMA Psychiatry* **72**, 757-766 (2015).
2. Verhulst, B., Neale, M.C. & Kendler, K.S. The heritability of alcohol use disorders: a meta-analysis of twin and adoption studies. *Psychol Med* **45**, 1061-1072 (2015).
3. Gelernter, J. & Polimanti, R. Genetics of substance use disorders in the era of big data. *Nat Rev Genet* **22**, 712-729 (2021).
4. Sanchez-Roige, S., *et al.* Genome-Wide Association Study Meta-Analysis of the Alcohol Use Disorders Identification Test (AUDIT) in Two Population-Based Cohorts. *Am J Psychiatry* **176**, 107-118 (2019).
5. Walters, R.K., *et al.* Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. *Nat Neurosci* **21**, 1656-1669 (2018).
6. Zhou, H., *et al.* Genome-wide meta-analysis of problematic alcohol use in 435,563 individuals yields insights into biology and relationships with other traits. *Nat Neurosci* **23**, 809-818 (2020).
7. Kranzler, H.R., *et al.* Genome-wide association study of alcohol consumption and use disorder in 274,424 individuals from multiple populations. *Nat Commun* **10**, 1499 (2019).
8. Gelernter, J., *et al.* Genome-wide Association Study of Maximum Habitual Alcohol Intake in >140,000 U.S. European and African American Veterans Yields Novel Risk Loci. *Biol Psychiatry* **86**, 365-376 (2019).
9. Deak, J.D., *et al.* Genome-Wide Investigation of Maximum Habitual Alcohol Intake in US Veterans in Relation to Alcohol Consumption Traits and Alcohol Use Disorder. *JAMA Netw Open* **5**, e2238880 (2022).
10. Liu, M., *et al.* Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237-244 (2019).
11. Saunders, G.R.B., *et al.* Genetic diversity fuels gene discovery for tobacco and alcohol use. *Nature* (2022).
12. Saunders, J.B., Aasland, O.G., Babor, T.F., de la Fuente, J.R. & Grant, M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II. *Addiction* **88**, 791-804 (1993).
13. Mallard, T.T., *et al.* Item-Level Genome-Wide Association Study of the Alcohol Use Disorders Identification Test in Three Population-Based Cohorts. *Am J Psychiatry* **179**, 58-70 (2022).
14. Johnson, E.C., *et al.* A large-scale genome-wide association study meta-analysis of cannabis use disorder. *Lancet Psychiatry* **7**, 1032-1045 (2020).
15. Hatoum, A.S., *et al.* The addiction risk factor: A unitary genetic vulnerability characterizes substance use disorders and their associations with common correlates. *Neuropsychopharmacology* **47**, 1739-1745 (2022).
16. Peterson, R.E., *et al.* Genome-wide Association Studies in Ancestrally Diverse Populations: Opportunities, Methods, Pitfalls, and Recommendations. *Cell* **179**, 589-603 (2019).
17. Bycroft, C., *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203-209 (2018).
18. Zheutlin, A.B., *et al.* Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia in 106,160 Patients Across Four Health Care Systems. *Am J Psychiatry* **176**, 846-855 (2019).
19. Gaziano, J.M., *et al.* Million Veteran Program: A mega-biobank to study genetic influences on health and disease. *J Clin Epidemiol* **70**, 214-223 (2016).

1015 20. Kurki, M.I.*, et al.* FinnGen: Unique genetic insights from combining isolated population and
1016 national health register data. *medRxiv* **doi:**
1017 **https://doi.org/10.1101/2022.03.03.22271360**(2022).
1018 21. Pedersen, C.B.*, et al.* The iPSYCH2012 case-cohort sample: new directions for unravelling genetic
1019 and environmental architectures of severe mental disorders. *Mol Psychiatry* **23**, 6-14 (2018).
1020 22. Bybjerg-Grauholm, J.*, et al.* The iPSYCH2015 Case-Cohort sample: updated directions for
1021 unravelling genetic and environmental architectures of severe mental disorders. *medRxiv* **doi:**
1022 **https://doi.org/10.1101/2020.11.30.20237768**(2020).
1023 23. Lind, P.*, et al.* Preliminary results from the Australian Genetics of Bipolar Disorder Study: A
1024 nation-wide cohort. *Psyarxive* **10.31234/osf.io/yd3sx**(2022).
1025 24. Byrne, E.M.*, et al.* Cohort profile: the Australian genetics of depression study. *BMJ Open* **10**,
1026 e032580 (2020).
1027 25. Couvy-Duchesne, B.*, et al.* Nineteen and Up study (19Up): understanding pathways to mental
1028 health disorders in young Australian twins. *BMJ Open* **8**, e018959 (2018).
1029 26. Gelernter, J.*, et al.* Genome-wide association study of alcohol dependence:significant findings in
1030 African- and European-Americans including novel risk loci. *Mol Psychiatry* **19**, 41-49 (2014).
1031 27. Zhou, H.*, et al.* Genome-wide meta-analysis of alcohol use disorder in East Asians.
1032 *Neuropsychopharmacology* **47**, 1791-1797 (2022).
1033 28. Kember, R.L.*, et al.* Genetic underpinnings of the transition from alcohol consumption to alcohol
1034 use disorder: shared and unique genetic architectures in a cross-ancestry sample. *medRxiv*
1035 **https://doi.org/10.1101/2021.09.08.21263302**(2021).
1036 29. Gelernter, J.*, et al.* Genomewide Association Study of Alcohol Dependence and Related Traits in
1037 a Thai Population. *Alcohol Clin Exp Res* **42**, 861-868 (2018).
1038 30. Trubetskoy, V.*, et al.* Mapping genomic loci implicates genes and synaptic biology in
1039 schizophrenia. *Nature* **604**, 502-508 (2022).
1040 31. Okbay, A.*, et al.* Polygenic prediction of educational attainment within and between families
1041 from genome-wide association analyses in 3 million individuals. *Nat Genet* **54**, 437-449 (2022).
1042 32. de Leeuw, C.A., Mooij, J.M., Heskes, T. & Posthuma, D. MAGMA: generalized gene-set analysis of
1043 GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).
1044 33. Watanabe, K., Taskesen, E., van Bochoven, A. & Posthuma, D. Functional mapping and
1045 annotation of genetic associations with FUMA. *Nat Commun* **8**, 1826 (2017).
1046 34. Barbeira, A.N.*, et al.* Exploring the phenotypic consequences of tissue specific gene expression
1047 variation inferred from GWAS summary statistics. *Nat Commun* **9**, 1825 (2018).
1048 35. GTEx Consortium. The GTEx Consortium atlas of genetic regulatory effects across human tissues.
1049 *Science* **369**, 1318-1330 (2020).
1050 36. Barbeira, A.N.*, et al.* Integrating predicted transcriptome from multiple tissues improves
1051 association detection. *PLoS genetics* **15**, e1007889 (2019).
1052 37. Sey, N.Y.A.*, et al.* A computational tool (H-MAGMA) for improved prediction of brain-disorder
1053 risk genes by incorporating brain chromatin interaction profiles. *Nat Neurosci* **23**, 583-593
1054 (2020).
1055 38. Mancuso, N.*, et al.* Probabilistic fine-mapping of transcriptome-wide association studies. *Nat*
1056 *Genet* **51**, 675-682 (2019).
1057 39. Ochoa, D.*, et al.* The next-generation Open Targets Platform: reimagined, redesigned, rebuilt.
1058 *Nucleic Acids Res* **51**, D1353-D1359 (2023).
1059 40. Ruan, Y.*, et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* **54**,
1060 573-580 (2022).

1061 41. Kember, R.L.*, et al.* Cross-ancestry meta-analysis of opioid use disorder uncovers novel loci with
1062 predominant effects in brain regions associated with addiction. *Nat Neurosci* **25**, 1279-1287
1063 (2022).
1064 42. Xu, K.*, et al.* Genome-wide association study of smoking trajectory and meta-analysis of smoking
1065 status in 842,000 individuals. *Nat Commun* **11**, 5302 (2020).
1066 43. Levey, D.F.*, et al.* Bi-ancestral depression GWAS in the Million Veteran Program and meta-
1067 analysis in >1.2 million individuals highlight new therapeutic directions. *Nat Neurosci* **24**, 954-
1068 963 (2021).
1069 44. Vujkovic, M.*, et al.* Discovery of 318 new risk loci for type 2 diabetes and related vascular
1070 outcomes among 1.4 million participants in a multi-ancestry meta-analysis. *Nat Genet* **52**, 680-
1071 691 (2020).
1072 45. Kember, R.L.*, et al.* Phenome-wide Association Analysis of Substance Use Disorders in a Deeply
1073 Phenotyped Sample. *Biol Psychiatry*, Aug 18:S0006-3223(0022)01515-01513. doi:
1074 01510.01016/j.biopsych.02022.01508.01010. Epub ahead of print. PMID: 36273948. (2022).
1075 46. Zhou, H.*, et al.* Association of OPRM1 Functional Coding Variant With Opioid Use Disorder: A
1076 Genome-Wide Association Study. *JAMA Psychiatry* **77**, 1072-1080 (2020).
1077 47. Deak, J.D.*, et al.* Genome-wide association study in individuals of European and African ancestry
1078 and multi-trait analysis of opioid use disorder identifies 19 independent genome-wide significant
1079 risk loci. *Mol Psychiatry* **27**, 3970-3979 (2022).
1080 48. Schwantes-An, T.H.*, et al.* Association of the OPRM1 Variant rs1799971 (A118G) with Non-
1081 Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of
1082 European-Ancestry Cohorts. *Behav Genet* **46**, 151-169 (2016).
1083 49. Notaras, M., Hill, R. & van den Buuse, M. The BDNF gene Val66Met polymorphism as a modifier
1084 of psychiatric disorder susceptibility: progress and controversy. *Mol Psychiatry* **20**, 916-930
1085 (2015).
1086 50. Karlsson Linner, R.*, et al.* Multivariate analysis of 1.5 million people identifies genetic
1087 associations with traits related to self-regulation and addiction. *Nat Neurosci* **24**, 1367-1376
1088 (2021).
1089 51. Schizophrenia Working Group of the Psychiatric Genomics, C. Biological insights from 108
1090 schizophrenia-associated genetic loci. *Nature* **511**, 421-427 (2014).
1091 52. Mealer, R.G.*, et al.* The schizophrenia risk locus in SLC39A8 alters brain metal transport and
1092 plasma glycosylation. *Sci Rep* **10**, 13162 (2020).
1093 53. Mealer, R.G.*, et al.* Glycobiology and schizophrenia: a biological hypothesis emerging from
1094 genomic research. *Mol Psychiatry* **25**, 3129-3139 (2020).
1095 54. Amit, Z. & Smith, B.R. A multi-dimensional examination of the positive reinforcing properties of
1096 acetaldehyde. *Alcohol* **2**, 367-370 (1985).
1097 55. Mews, P.*, et al.* Alcohol metabolism contributes to brain histone acetylation. *Nature* **574**, 717-
1098 721 (2019).
1099 56. Pandey, S.C., Ugale, R., Zhang, H., Tang, L. & Prakash, A. Brain chromatin remodeling: a novel
1100 mechanism of alcoholism. *J Neurosci* **28**, 3729-3737 (2008).
1101 57. Carlsson, C. & Gullberg, B. A double blind study with melperone and placebo in the treatment of
1102 chronic alcoholics. *Int J Clin Pharmacol Biopharm* **16**, 331-332 (1978).
1103 58. Carlsson, C., Gullberg, B., Hostery, U. & Christensson, E. A double-blind study of melperone and
1104 placebo in hospitalized chronic alcoholics in postintoxication phase. *Int J Clin Pharmacol*
1105 *Biopharm* **17**, 341-345 (1979).
1106 59. Farokhnia, M.*, et al.* Spironolactone as a potential new pharmacotherapy for alcohol use
1107 disorder: convergent evidence from rodent and human studies. *Mol Psychiatry* **27**, 4642-4652
1108 (2022).

1109 60. Sychla, H., Grunder, G. & Lammertz, S.E. Comparison of Clomethiazole and Diazepam in the
1110 Treatment of Alcohol Withdrawal Syndrome in Clinical Practice. *Eur Addict Res* **23**, 211-218
1111 (2017).
1112 61. Hunter-Zinck, H.*, et al.* Genotyping Array Design and Data Quality Control in the Million Veteran
1113 Program. *Am J Hum Genet* **106**, 535-548 (2020).
1114 62. Price, A.L.*, et al.* Principal components analysis corrects for stratification in genome-wide
1115 association studies. *Nat Genet* **38**, 904-909 (2006).
1116 63. Galinsky, K.J.*, et al.* Fast Principal-Component Analysis Reveals Convergent Evolution of ADH1B
1117 in Europe and East Asia. *Am J Hum Genet* **98**, 456-472 (2016).
1118 64. 1000 Genomes Project Consortium. A global reference for human genetic variation. *Nature* **526**,
1119 68-74 (2015).
1120 65. Delaneau, O., Zagury, J.F., Robinson, M.R., Marchini, J.L. & Dermitzakis, E.T. Accurate, scalable
1121 and integrative haplotype estimation. *Nat Commun* **10**, 5436 (2019).
1122 66. Das, S.*, et al.* Next-generation genotype imputation service and methods. *Nat Genet* **48**, 1284-
1123 1287 (2016).
1124 67. Loh, P.R., Kichaev, G., Gazal, S., Schoech, A.P. & Price, A.L. Mixed-model association for biobank-
1125 scale datasets. *Nat Genet* **50**, 906-908 (2018).
1126 68. Zhou, W.*, et al.* Efficiently controlling for case-control imbalance and sample relatedness in
1127 large-scale genetic association studies. *Nat Genet* **50**, 1335-1341 (2018).
1128 69. Lam, M.*, et al.* RICOPILI: Rapid Imputation for COnsortias PIpeLIne. *Bioinformatics* **36**, 930-933
1129 (2020).
1130 70. Demontis, D.*, et al.* Genome-wide analyses of ADHD identify 27 risk loci, refine the genetic
1131 architecture and implicate several cognitive domains. *medRxiv*
1132 **https://doi.org/10.1101/2022.02.14.22270780**, 2022.2002.2014.22270780 (2022).
1133 71. Chang, C.C.*, et al.* Second-generation PLINK: rising to the challenge of larger and richer datasets.
1134 *Gigascience* **4**, 7 (2015).
1135 72. Heath, A.C.*, et al.* A quantitative-trait genome-wide association study of alcoholism risk in the
1136 community: findings and implications. *Biol Psychiatry* **70**, 513-518 (2011).
1137 73. Zhou, X. & Stephens, M. Efficient multivariate linear mixed model algorithms for genome-wide
1138 association studies. *Nat Methods* **11**, 407-409 (2014).
1139 74. Willer, C.J., Li, Y. & Abecasis, G.R. METAL: fast and efficient meta-analysis of genomewide
1140 association scans. *Bioinformatics* **26**, 2190-2191 (2010).
1141 75. Yang, J.*, et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies
1142 additional variants influencing complex traits. *Nat Genet* **44**, 369-375, S361-363 (2012).
1143 76. International HapMap Consortium*, et al.* Integrating common and rare genetic variation in
1144 diverse human populations. *Nature* **467**, 52-58 (2010).
1145 77. Bulik-Sullivan, B.K.*, et al.* LD Score regression distinguishes confounding from polygenicity in
1146 genome-wide association studies. *Nat Genet* **47**, 291-295 (2015).
1147 78. Brown, B.C., Asian Genetic Epidemiology Network Type 2 Diabetes, C., Ye, C.J., Price, A.L. &
1148 Zaitlen, N. Transethnic Genetic-Correlation Estimates from Summary Statistics. *Am J Hum Genet*
1149 **99**, 76-88 (2016).
1150 79. LaPierre, N.*, et al.* Identifying causal variants by fine mapping across multiple studies. *PLoS*
1151 *genetics* **17**, e1009733 (2021).
1152 80. GTEx Consortium. Genetic effects on gene expression across human tissues. *Nature* **550**, 204-
1153 213 (2017).
1154 81. Laakso, M.*, et al.* The Metabolic Syndrome in Men study: a resource for studies of metabolic and
1155 cardiovascular diseases. *J Lipid Res* **58**, 481-493 (2017).

1156 82. Ligthart, L.*, et al.* The Netherlands Twin Register: Longitudinal Research Based on Twin and
1157 Twin-Family Designs. *Twin Res Hum Genet* **22**, 623-636 (2019).
1158 83. Turpeinen, H.*, et al.* A genome-wide expression quantitative trait loci analysis of proprotein
1159 convertase subtilisin/kexin enzymes identifies a novel regulatory gene variant for FURIN
1160 expression and blood pressure. *Hum Genet* **134**, 627-636 (2015).
1161 84. Hoffman, G.E.*, et al.* CommonMind Consortium provides transcriptomic and epigenomic data for
1162 Schizophrenia and Bipolar Disorder. *Sci Data* **6**, 180 (2019).
1163 85. Subramanian, A.*, et al.* A Next Generation Connectivity Map: L1000 Platform and the First
1164 1,000,000 Profiles. *Cell* **171**, 1437-1452 e1417 (2017).
1165 86. So, H.C.*, et al.* Analysis of genome-wide association data highlights candidates for drug
1166 repositioning in psychiatry. *Nat Neurosci* **20**, 1342-1349 (2017).
1167 87. Viechtbauer, W. Conducting Meta-Analyses in R with the metafor Package. *Journal of Statistical*
1168 *Software* **36(3), 1–48**(2010).
1169 88. Ge, T., Chen, C.Y., Ni, Y., Feng, Y.A. & Smoller, J.W. Polygenic prediction via Bayesian regression
1170 and continuous shrinkage priors. *Nat Commun* **10**, 1776 (2019).
1171 89. Bulik-Sullivan, B.*, et al.* An atlas of genetic correlations across human diseases and traits. *Nat*
1172 *Genet* **47**, 1236-1241 (2015).
1173 90. Luo, Y.*, et al.* Estimating heritability and its enrichment in tissue-specific gene sets in admixed
1174 populations. *Hum Mol Genet* **30**, 1521-1534 (2021).
1175 91. Boutin, N.T.*, et al.* The Evolution of a Large Biobank at Mass General Brigham. *J Pers Med*
1176 **12**(2022).
1177 92. Verma, A.*, et al.* The Penn Medicine BioBank: Towards a Genomics-Enabled Learning Healthcare
1178 System to Accelerate Precision Medicine in a Diverse Population. *J Pers Med* **12**(2022).
1179 93. Abraham, G., Qiu, Y. & Inouye, M. FlashPCA2: principal component analysis of Biobank-scale
1180 genotype datasets. *Bioinformatics* **33**, 2776-2778 (2017).
1181 94. Loh, P.R.*, et al.* Reference-based phasing using the Haplotype Reference Consortium panel. *Nat*
1182 *Genet* **48**, 1443-1448 (2016).
1183 95. Denny, J.C.*, et al.* Systematic comparison of phenome-wide association study of electronic
1184 medical record data and genome-wide association study data. *Nature biotechnology* **31**, 1102-
1185 1110 (2013).

1186